Literature DB >> 26882235

Innocent Until Proven Guilty.

Heather E Moss1, Tiffani S Stroup, Amy Y Lin, Oliver W Graf, Aaron M Halfpenny, Howard L Lipton, Ari M Blitz, Tibor Valyi-Nagy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26882235      PMCID： PMC4758521          DOI： 10.1097/WNO.0000000000000338

Source DB:  PubMed          Journal:  J Neuroophthalmol        ISSN： 1070-8022            Impact factor:   3.042


× No keyword cloud information.
  11 in total

1.  Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays.

Authors:  P J Waters; A McKeon; M I Leite; S Rajasekharan; V A Lennon; A Villalobos; J Palace; J N Mandrekar; A Vincent; A Bar-Or; S J Pittock
Journal:  Neurology       Date:  2012-02-01       Impact factor: 9.910

Review 2.  Pathology of demyelinating diseases.

Authors:  Bogdan F Gh Popescu; Claudia F Lucchinetti
Journal:  Annu Rev Pathol       Date:  2012       Impact factor: 23.472

3.  NMO-IgG detected in CSF in seronegative neuromyelitis optica.

Authors:  E C Klawiter; E Alvarez; J Xu; A R Paciorkowski; L Zhu; B J Parks; A H Cross; R T Naismith
Journal:  Neurology       Date:  2009-03-24       Impact factor: 9.910

Review 4.  Immunopathogenesis of neuromyelitis optica.

Authors:  Michael Levy; Brigitte Wildemann; Sven Jarius; Benjamine Orellano; Saranya Sasidharan; Martin S Weber; Olaf Stuve
Journal:  Adv Immunol       Date:  2014       Impact factor: 3.543

Review 5.  Biology of AQP4 and anti-AQP4 antibody: therapeutic implications for NMO.

Authors:  A S Verkman; Puay-Wah Phuan; Nithi Asavapanumas; Lukmanee Tradtrantip
Journal:  Brain Pathol       Date:  2013-11       Impact factor: 6.508

Review 6.  Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status.

Authors:  Douglas Kazutoshi Sato; Marco Aurelio Lana-Peixoto; Kazuo Fujihara; Jerome de Seze
Journal:  Brain Pathol       Date:  2013-11       Impact factor: 6.508

7.  Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy.

Authors:  M H Barnett; J W Prineas; M E Buckland; J D E Parratt; J D Pollard
Journal:  Mult Scler       Date:  2011-08-25       Impact factor: 6.312

8.  Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions.

Authors:  Bogdan F G Popescu; Yong Guo; Mark E Jentoft; Joseph E Parisi; Vanda A Lennon; Sean J Pittock; Brian G Weinshenker; Dean M Wingerchuk; Caterina Giannini; Imke Metz; Wolfgang Brück; Elizabeth A Shuster; Jonathan Carter; Clara D Boyd; Stacey Lynn Clardy; Bruce A Cohen; Claudia F Lucchinetti
Journal:  Neurology       Date:  2014-12-10       Impact factor: 9.910

9.  Neuromyelitis optica lesions may inform multiple sclerosis heterogeneity debate.

Authors:  Wolfgang Brück; Bogdan Popescu; Claudia F Lucchinetti; Silva Markovic-Plese; Ralf Gold; Dietmar Rudolf Thal; Imke Metz
Journal:  Ann Neurol       Date:  2012-09       Impact factor: 10.422

Review 10.  Use of therapeutic plasma exchange in the management of acute hemorrhagic leukoencephalitis: a case report and review of the literature.

Authors:  Lori J Ryan; Robert Bowman; Nicole Dodge Zantek; Gregory Sherr; Robert Maxwell; H Brent Clark; David C Mair
Journal:  Transfusion       Date:  2007-06       Impact factor: 3.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.